Practice
Featured experience
GSK collaboration with Flagship Pioneering
We are advising GSK on the transaction
Azul $800 million secured notes offering
The senior secured notes are due 2028
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
NBCUniversal partnership with MultiChoice to relaunch Showmax using Peacock
We are advising NBCUniversal on the transaction to relaunch MultiChoice’s Showmax service using the Peacock platform
Davis Polk Advises MSCI on Its Acquisition of Insignis
Davis Polk is advising MSCI Inc. in connection with its acquisition of all of the assets of Insignis, Inc. Financial terms…
Davis Polk Advises SS&C on Its Acquisition of Primatics Financial
Davis Polk is advising SS&C Technologies Holdings, Inc. in connection with its approximately $122 million acquisition of…
Davis Polk Advises Roper Technologies on Its Acquisition of RF IDeas
Davis Polk advised Roper Technologies, Inc. in connection with its acquisition of RF IDeas, Inc. The financial terms of the…
Davis Polk Advises SS&C on Its Acquisition of Citigroup’s Alternative Investor Services Business
Davis Polk is advising SS&C Technologies Holdings, Inc. in connection with its acquisition of Citigroup’s Alternative…
Global Blood Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $138 million initial public offering of common…
Aimmune Therapeutics, Inc. $183.9 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $183.9 million initial public offering of Aimmune Technologies,…
Natera, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of 10,000,000…
Davis Polk Advises Hotel Urbano on its Strategic Partnership with Priceline
Davis Polk advised Hotel Urbano in connection with its strategic partnership with The Priceline Group. The partnership…
Davis Polk Advises Tailwind Capital on the Sale of ReTrans
Davis Polk is advising Tailwind Capital in connection with the sale of ReTrans Inc. to The Kuehne + Nagel Group. The…
Cynapsus Therapeutics Inc. $72.5 Million Initial Public Offering
Davis Polk advised the underwriters in connection with the $72.5 million U.S. initial public offering of 5,175,000 common…